In India, Roche Diagnostics Grows At Twice The Market Rate, But Public Awareness Still Low
This article was originally published in PharmAsia News
MUMBAI - Roche Diagnostics India (Pvt) Ltd. Chairman and Managing Director Bhuvnesh Agarwal believes the company has benefited from the unprecedented surge in market growth, but still finds public awareness to be an issue when it comes to the most advanced diagnostics available to patients
You may also be interested in...
Roche Diagnostics Cites Ind-Swift’s “Hunger To Grow” As The Two Team Up To Market Heart Attack Diagnostic In India
Roche Diagnostics chooses Ind-Swift in India as marketing partner for TROP T assay to detect heart attacks.
MUMBAI - Novartis Diagnostics dominated a large number of Western markets with its nucleic acid testing assays for donated blood, and now the Novartis unit is aiming to mirror that success in the Asia-Pacific region by aligning with private institutions, collaborating with progressive states in countries like India and working closely with non-governmental organizations
Roche Diagnostics’ Asia Pacific Managing Director Roland Diggelmann On Delivering Personalized Medicine: An Interview With PharmAsia News (Part 1 of 2)
Roche Diagnostics has identified Asia Pacific, including India, as its fastest-growing region, which has been consistently growing at 30 percent for the company. Roland Diggelmann, Managing Director at Roche Diagnostics Asia Pacific, told PharmAsia News' Mumbai bureau that with a slew of product launches the region will continue to play a bigger role in the global plans of the company. Diggelmann, who has several countries like Australia, China, Hong Kong, India, Indonesia, Korea, Malaysia, New Zealand, Pakistan, Philippines, Singapore, Taiwan, Thailand, and Vietnam under his charge, discusses Roche's plans in this interview.